Ambeed.cn

首页 / 抑制剂/激动剂 / 神经信号通路 / AChR / Aclidinium Bromide

阿地溴铵 /Aclidinium Bromide 98%

货号:A110489 同义名: LAS 34273;LAS-W 330 Ambeed 开学季,买赠积分,赢豪礼

Aclidinium bromide is a long-acting, inhaled muscarinic antagonist as a maintenance treatment for chronic obstructive pulmonary disease (COPD).

Aclidinium Bromide 化学结构 CAS号:320345-99-1
Aclidinium Bromide 化学结构
CAS号:320345-99-1
Aclidinium Bromide 3D分子结构
CAS号:320345-99-1
Aclidinium Bromide 化学结构 CAS号:320345-99-1
Aclidinium Bromide 3D分子结构 CAS号:320345-99-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Aclidinium Bromide 纯度/质量文件 产品仅供科研

货号:A110489 标准纯度: 98%
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell,2024. Ambeed. [ A125712 ]
Cancer Discov., 2024. Ambeed. [ A285925 ]
JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]
JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]
EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]
更多 >
产品名称 AChE AChR mAChR nAChR 其他靶点 纯度
Donepezil +++

bAChE, IC50: 8.12 nM

hAChE, IC50: 11.6 nM

98%
Loganin ++

AChE, IC50: 3.95 μM

99%+
topride HCl ++

AChE, IC50: 2.04 μM

98%
Dehydroevodiamine HCl 99%+
Jatrorrhizine ++

AChE, IC50: 872 nM

99%+
Palmatine ++

AChE, IC50: 0.51 μM

98%
(-)-Huperzine A ++++

AChE (G4 form), Ki: 7 nM

98%
Galanthamine HBr ++

AChE, IC50: 0.35 μM

98%
Trospium chloride 99%
Tiotropium Bromide Monohydrate 98+%
Gallamine Triethiodide +

AChR, IC50: 68.0 μM

98%
Hexamethonium Bromide 99%
Pancuronium dibromide 98%
Neostigmine bromide 98%
Orphenadrine citrate 98%
Oxybutynin 98%
Irsogladine PDE 98%
Pyridostigmine bromide 99+%
Rivastigmine +

AChR, IC50: 5.5 μM

98%
Paroxetine hydrochloride 97%
Rocuronium Bromide 98%
Tropicamide +++

M4 mAChR, IC50: 8 nM

98%
Diphenmanil methylsulfate 98%
Umeclidinium bromide 95%
Otilonium bromide 98%
Flavoxate HCl +

mAChR, IC50: 12.2 μM

98%
Ipratropium bromide 98%
Diphenidol HCl 98%
Darifenacin hydrobromide ++++

M3 mAChR, pKi: 8.9

98%
Aclidinium Bromide ++++

M4 mAChR, Ki: 0.21 nM

M2 mAChR, Ki: 0.1 nM

98%
Oxybutynin chloride 99%
Pentoxyverine citrate 98%
Solifenacin 98%
Catharanthine 98%
Benzethonium chloride +++

α4β2 nAChRs, IC50: 49 nM

α7 nAChRs, IC50: 122 nM

99+%
Vinblastine sulfate +

nAChR, IC50: 8.9 μM

99%
PNU-120596 ++

α7 nAChR, EC50: 216 nM

99+%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Aclidinium Bromide 生物活性

靶点
  • mAChR

    M4 mAChR, Ki:0.21 nM

    M2 mAChR, Ki:0.1 nM

描述 Aclidinium bromide is a novel potent, long-acting inhaled muscarinic antagonist with a fast onset of action, a long duration of effect, and a favorable cardiovascular safety profile. Aclidinium Bromide inhibits human muscarinic AChR M1, M2, M3, M4 and M5 with Ki of 0.1 nM, 0.14 nM, 0.14 nM, 0.21 nM and 0.16 nM, respectively[3]. Aclidinium was rapidly hydrolysed into carboxylic acid and alcohol derivatives in guinea pig, rat, human and dog plasma with half-lives of 38, 11.7, 2.4 and 1.8 min, respectively. Aclidinium (1 mg/ml) produces a potent and sustained bronchoprotection (72%–88.4%) over the 120-min study period in anaesthetised guinea pigs[4]. Aclidinium (0.1 μM) inhibits carbachol and TGF-β1 induced upregulation of collagen type I and α-SMA mRNA and protein expression in human bronchial fibroblasts. Aclidinium (0.1 μM) inhibits TGF-β1 induced upregulation of ChAT expression in human bronchial fibroblasts. Aclidinium (0.1 μM) inhibits carbachol- and TGF-β1-induced increases in ERK1/2 phosphorylation and RhoA-GTP formation in human bronchial fibroblasts. Aclidinium pretreatment prevents the upregulation of M1 and M3, but not M2 downregulation induced by carbachol or TGF-β1 in human lung fibroblasts. Aclidinium (0.1 μM) dose-dependently inhibits the TGF-β1 and carbachol-induced cell proliferation of human lung fibroblasts[5]. The expression of Bcl-2 declined, and Bax and Caspase 3 increased in A549 cells treated with Aclidinium Bromide. Additionally, Aclidinium Bromide suppressed the PI3K/AKT signaling pathway in lung cancer A549 cells. CCK-8 showed that Aclidinium Bromide could suppress the growth of lung cancer cells A549[6].

Aclidinium Bromide 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03662711 Pulmonary Disease, Chronic Obs... 展开 >>tructive 收起 << Phase 4 Recruiting September 2020 Italy ... 展开 >> Istituti Clinici Scientifici Maugeri S.p.A - SB, Pneumologia Riabilitativa Recruiting Telese Terme, Benevento, Italy, 82037 Contact: Mauro Maniscalco       mauro.maniscalco@icsmaugeri.it    Ospedale San Giovanni di Dio, UOC Medicina Interna Not yet recruiting Crotone, Calabria, Italy, 88900 Contact: Raffaele Costa       costa.raffaele@libero.it    Ospedale "Jazzolino" ASP, UOC Medicina Interna Not yet recruiting Vibo Valentia, Calabria, Italy, 89900 Contact: Luigi Anastasio       luigi.anastasio@aliceposta.it    Ospedale civile di Battipaglia, Medicina, Servizio di Allergologia e Immunologia Clinica Not yet recruiting Battipaglia, Campania, Italy, 84091 Contact: Vincenzo Patella       pobattipaglia.allerg@aslsalerno.it    Università degli studi di Modena e Reggio Emilia, Clinica Malattie dell'apparato Respiratorio Recruiting Modena, Emilia Romagna, Italy, 41124 Contact: Enrico Clini       enrico.clini@unimore.it    Azienda Ospedaliero-universitaria di Parma, Clinica pneumologica Not yet recruiting Parma, Emilia Romagna, Italy, 43126 Contact: Alfredo Chetta       chetta@unipr.it    AUSL - IRCCS di Reggio Emilia, Pneumologia Not yet recruiting Reggio Emilia, Emilia Romagna, Italy, 42122 Contact: Nicola Facciolongo       nicolacosimo.facciolongo@ausl.re.it    UNIVERSITà DEGLI STUDI DI FERRARA, CLINICA DI MALATTIE DELL'APPARATO RESPIRATORIO Recruiting Ferrara, FE, Italy, 44100 Contact: Alberto Papi, MD    +390532210420    ppa@unife.it    Sub-Investigator: Brunilda Marku, MD          Sub-Investigator: Giacomo Forini, MD          Sub-Investigator: Marianna Padovani, MD          Università degli studi di Foggia, ospedale pneumologico D'Avanzo, unità operativa di malattie dell'apparato respiratorio Not yet recruiting Foggia, FG, Italy Contact: Maria Pia Foschino, MD    +390881617832    mfoschino@qubisoft.it    Ospedale S. Maria degli Angeli - AAS5 Friuli Occidentale, Pneumologia Not yet recruiting Pordenone, Friuli Venezia Giulia, Italy, 33100 Contact: Carlo Barbetta       carlo.barbetta@aas5.sanita.fvg.it    Policlinico Universitario Campus Biomedico di Roma, Medicina Interna e Geriatria Not yet recruiting Roma, Lazio, Italy, 00128 Contact: Raffaele Antonello Incalzi       r.antonelli@unicampus.it    Università di Roma "Tor Vergata", Dipartimento di Medicina dei Sistemi, Malattie dell'apparato respiratorio Not yet recruiting Roma, Lazio, Italy, 00133 Contact: Paola Rogliani       paola.rogliani@uniroma2.it    ASL2 Savonese, Ospedale S. Corona, Pneumologia Not yet recruiting Pietra Ligure, Liguria, Italy, 17027 Contact: Manlio Milanese       m.milanese@asl2.liguria.it    Ospedale San Paolo, Medicina 2 e cure Intermedie Not yet recruiting Savona, Liguria, Italy, 17100 Contact: Paola Gnerre       pgnerre@yahoo.it    Ospedale Figlie di San Camillo, Medicina Interna Not yet recruiting Cremona, Lombardia, Italy, 26100 Contact: Maurizio Marvisi       mmarvisi@alice.it    ASST Ovest Milanese - Ospedale civile di Legnano, Medicina interna Not yet recruiting Legnano, Lombardia, Italy, 20025 Contact: Giorgio Bonardi       giorgio.bonardi@asst-ovestmi.it    Ospedale "Carlo Poma", Struttura Complessa Pneumologia e UTIR Not yet recruiting Mantova, Lombardia, Italy, 46100 Contact: Giuseppe De Donno       giuseppe.dedonno@asst-mantova.it    Ospedale "L. Sacco" - Polo Universitario ASST Fatebenefratelli Sacco, Pneumologia Not yet recruiting Milano, Lombardia, Italy, 20157 Contact: Pierachille Santus       pierachille.santus@unimi.it    Fondazione IRCCS Policlinico San Matteo, Pneumologia Not yet recruiting Pavia, Lombardia, Italy, 27100 Contact: Angelo Corsico       corsico@unipv.it    Istituti Clinici Scientifici Fondazione Maugeri, Pneumologia Riabilitativa Not yet recruiting Pavia, Lombardia, Italy, 27100 Contact: Piero Ceriana       piero.ceriana@icsmaugeri.it    Istituti Clinici Scientifici maugeri, Pneumologia Riabilitativa Not yet recruiting Tradate, Lombardia, Italy, 21049 Contact: Antonio Spanevello       antonio.spanevello@icsmaugeri.it    Ospedali Riuniti di Ancona, Pneumologia Not yet recruiting Torrette, Marche, Italy, 60030 Contact: Stefano Gasparini       s.gasparini52@gmail.com    Ospedale F. Veneziale, Medicina Interna Not yet recruiting Isernia, Molise, Italy, 86170 Contact: Cecilia Politi       cecilia.politi@asrem.org    Università degli Studi di Palermo, Ospedale "V. Cervello" Not yet recruiting Palermo, Pa, Italy, 90146 Contact: Nicola Scichilone, MD, PHD    0916802652    n.scichilone@libero.it    Università degli studi di Padova, dipartimento di Pneunmologia Not yet recruiting Padova, PD, Italy Contact: Marina Saetta, MD    +390498213732    marina.saetta@unipd.it    Ospedale Maggiore, Medicina interna Not yet recruiting Chieri, Piemonte, Italy, 10023 Contact: Roberto Frediani       rfrediani1@alice.it    Ospedale di Ceva, Medicina interna Not yet recruiting San Bernardino, Piemonte, Italy, 12073 Contact: Carlo Lorenzo Muzzulini       carlolorenzo.muzzulini@aslcn1.it    Ospedale Civile SS. Annunziata, Medicina interna Not yet recruiting Savigliano, Piemonte, Italy, 12038 Contact: Giovanni Gulli       giovanni.gulli@aslcn1.it    Policlinico Ospedaliero di Varese - Ospedale di Circolo e Fondazione Macchi, Medicina interna Not yet recruiting Varese, Piemonte, Italy, 21100 Contact: Francesco Dentali       fdentali@libero.it    Istituti Clinici Scientifici Maugeri, Pneumologia Riabilitativa Recruiting Veruno, Piemonte, Italy, 28010 Contact: Bruno Balbi       bruno.balbi@icsmaugeri.it    Università degli studi di Pisa, Ospedale Cisanello, unità operativa di Pneumologia Not yet recruiting Pisa, PI, Italy Contact: Pierluigi Paggiaro, MD    +39050995266    ppaggiaro@qubisoft.it    Istituti Clinici Scientifici Maugeri, Pneumologia Riabilitativa Not yet recruiting Cassano Delle Murge, Puglia, Italy, 70020 Contact: Maria Aliani       maria.aliani@icsmaugeri.it    Ospedale "G. Tatarella", Medicina Interna Not yet recruiting Cerignola, Puglia, Italy, 71042 Contact: Francesco Ventrella       f.ventrella@libero.it    Azienda Ospedaliero Universitaria "Policlinico Vittorio Emanuele", Pneumologia Not yet recruiting Catania, Sicilia, Italy, 95123 Contact: Claudia Crimi       dott.claudiacrimi@gmail.com    Presidio ospedaliero Muscatello di Augusta, Medicina Interna Not yet recruiting Siracusa, Sicilia, Italy, 96100 Contact: Roberto Risicato       r.risicato@inwind.it    Azienda Ospedaliero-universitaria Careggi, Medicina per la alta complessità Assistenziale 1 Not yet recruiting Firenze, Toscana, Italy, 50134 Contact: Carlo Nozzoli       nozzolicarlo@gmail.com    Azienda Ospedaliero-universitaria Careggi, Medicina per la alta complessità Assistenziale 2 Not yet recruiting Firenze, Toscana, Italy, 50134 Contact: Francesco Corradi       francescocorradi72@gmail.com    Università degli studi di Siena, UOC Malattie respiratorie Not yet recruiting Siena, Toscana, Italy, 53100 Contact: Elena Bargagli       bargagli2@gmail.com    Ospedale di Cattinara, unità operativa di pneumologia Not yet recruiting Trieste, TS, Italy Contact: Marco Confalonieri, MD    +390403993136    marco.confalonieri@aots.sanita.fvg.it 收起 <<
NCT02165826 - Completed - -
NCT02165826 Chronic Obstructive Pulmonary ... 展开 >>Disease (COPD) 收起 << Phase 3 Completed - Slovakia ... 展开 >> Bardejov, Slovakia Spisska Nova Ves, Slovakia 收起 <<

Aclidinium Bromide 参考文献

[1]Beier J, Mroz R,.Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study. Int J Chron Obstruct Pulmon Dis. 2017 Jun 14;12:1731-1740.

[2]Sentellas S, Ramos I,. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010 Mar 18;39(5):283-90.

[3]Gavaldà A, Miralpeix M, Ramos I, Otal R, Carreño C, Viñals M, Doménech T, Carcasona C, Reyes B, Vilella D, Gras J, Cortijo J, Morcillo E, Llenas J, Ryder H, Beleta J. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther. 2009 Nov;331(2):740-51

[4]Sentellas S, Ramos I, Albertí J, Salvà M, Antón F, Miralpeix M, Beleta J, Gavaldà A. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010 Mar 18;39(5):283-90

[5]Milara J, Serrano A, Peiró T, Gavaldà A, Miralpeix M, Morcillo EJ, Cortijo J. Aclidinium inhibits human lung fibroblast to myofibroblast transition. Thorax. 2012 Mar;67(3):229-37

[6]Lin G, He Y, Han D, Shi D, Liu T, Gao Y, Guan W, Cheng G. Aclidinium Bromide holds promising inhibitory effects in A549 lung cancer cells potentials by regulating PI3K / AKT signaling pathway. J BUON. 2019 Mar-Apr;24(2):560-565

Aclidinium Bromide 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.77mL

0.35mL

0.18mL

8.86mL

1.77mL

0.89mL

17.71mL

3.54mL

1.77mL

Aclidinium Bromide 技术信息

CAS号320345-99-1
分子式C26H30BrNO4S2
分子量 564.555
别名 LAS 34273;LAS-W 330;Aclidinium (bromide)
运输蓝冰
存储条件

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 35 mg/mL(62 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。